Optimizing Peptide Production With PUREcoli™: A Smarter Microbial Approach To Therapeutic Peptide Manufacturing

Rapid growth in therapeutic peptides, including GLP-1 analogs, is placing new pressure on traditional solid-phase peptide synthesis. High raw material costs, environmental burdens, and scale-up constraints are prompting manufacturers to consider more efficient production methods. Microbial expression using KBI Biopharma’s proprietary PUREplatform™ and PUREcoli™ technology offers a scalable, cost-effective alternative designed to address these challenges. A real-world liraglutide example demonstrates how strain engineering, tag optimization, and scalable fermentation workflows can increase yields, lower manufacturing costs, and simplify downstream processing.

Watch to explore a more scalable path for peptide manufacturing.